Country Overviews Market Research Reports & Industry Analysis
Country Overviews Industry Research & Market Reports
-
Iran Pharmaceuticals & Healthcare Q3 2020
... the role of US sanctions in further undermining the economy, infrastructure, and public healthfacilities. This mix of factors has resulted in Iran becoming one of the region's most adversely affected nations, with the governmentpledging to ... Read More
-
Nigeria Pharmaceuticals & Healthcare Q3 2020
... country’s attractiveness to innovative drugmakers. This is exacerbated by regulatory inefficiencies and high prevalence ofcounterfeit medicines. The goal of achievement of universal healthcare by 2030 will continue to be threatened by a number ofstructural issues. Read More
-
Peru Pharmaceuticals & Healthcare Q3 2020
... to boost the capacity of a chronically underfunded healthcaresystem. Relatively increased levels of public expenditure on medical services will be maintained despite restrictions on governmentspending due to macroeconomic dynamics. Beyond the pandemic, medicine sales in ... Read More
-
Switzerland Pharmaceuticals & Healthcare Q3 2020
... market growth, Switzerland employs relatively liberalpricing rules that result in the country having the second-highest medicine spending per capita globally after the US. This helpscreate an attractive investment location for firms. Indeed, Switzerland contains multiple ... Read More
-
United States Pharmaceuticals & Healthcare Q3 2020
... will also increasepersonal spending. The complex and decentralised healthcare system in the US will inhibit the containment of the disease. Therewill be increased calls to replace the hybrid payer landscape with a single-payer healthcare system. Read More
-
Cambodia Pharmaceuticals & Healthcare Q3 2020
... funds, including international aid will contribute towardsimproving the country’s healthcare capacity. Despite the still-underdeveloped health system, the significant percentage ofpopulation living in rural areas suggests the coronavirus will not spread as rapidly as in developed ... Read More
-
Ireland Pharmaceuticals & Healthcare Q3 2020
... widespread, and along with the healthcare sector revision, we have revised real GDP growth forecastsfor 2020 as the country is pushed into a recession. Growing numbers of cases and deaths are resulting in increased stresses ... Read More
-
Japan Pharmaceuticals & Healthcare Q2 2020
... growth. This is expected to change in the medium-to-long term though asan ageing population, 20% of the population is over 65, and a very high health spending per capita will fuel demand for high-valueinnovative medicines. Read More
-
Netherlands Pharmaceuticals & Healthcare Q3 2020
... we also expect innovative drug sales to continue to decline in theshort term, we see companies in the Netherlands continue to seek new treatments and vaccines to help the fight against thecoronavirus. The government will ... Read More
-
New Zealand Pharmaceuticals & Healthcare Q3 2020
... However, strict pricing continues to be an issue formultinational companies in particular, given the limited potential return on their investment in high-tech treatments. Thoseconsiderations as well as the relatively small number of coronavirus infections mean ... Read More
-
Health Care Sector
... facilities. Major companies include Ascension Health, HCA, Kaiser Permanente, and Tenet Healthcare (all based in the US), as well as Fresenius (Germany), National Hospital Organization (Japan), and Ramsay Health Care (Australia). COMPETITIVE LANDSCAPE Health care ... Read More
-
Czech Republic Pharmaceuticals & Healthcare Q3 2020
... account of its rising urbanisation levels and prevalence of non-communicable diseases. However, the main risks to our centralpharmaceutical and healthcare forecasts are to the downside amid growing deficits in public healthcare funds and cost-containment policies. Read More
-
Singapore Pharmaceuticals & Healthcare Q3 2020
... outlook is uncertain asthe Covid-19 outbreak continues to spread and the immediate need to address the uncontrolled spread will affect the economy -we forecast the country to head into a recession - and the pharmaceuticals ... Read More
-
Sweden Pharmaceuticals & Healthcare Q3 2020
... place some limits on market potential, however, the high proportion of over 65 year olds is broadly a positive detail forthe industry. The government will remain committed towards supporting healthcare innovations and personalised medicaltreatment development, ... Read More
-
Jordan Pharmaceuticals & Healthcare Q3 2020
... sector andgovernment support for medical tourism. The market's fundamentals are sound and should ensure steady longer-term growth, withplans to expand Government healthcare cover across the country also supportive. However, as with many other countriesaround the ... Read More
-
Costa Rica Pharmaceuticals & Healthcare Q3 2020
... adaptation by the health system,including resources diverted towards controlling the emergency outbreak, will continue to be carried out. Based on market growthfundamentals, Costa Rica's pharmaceuticals and healthcare spending will post robust growth over the next ... Read More
-
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia
... information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. ... Read More
-
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Poland
... information and analysis on the healthcare, regulatory and reimbursement landscape in the Poland. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of ... Read More
-
Bahrain Pharmaceuticals & Healthcare Q3 2020
... by a rising burden of non-communicablediseases, an ageing population and the combination of strong purchasing power with a preference for high-value innovativemedicines. Healthcare system modernisation via public-private partnerships will be high on the government’s agenda. Read More
-
Canada Pharmaceuticals & Healthcare Q3 2020
... forecast toreflect recent medicine price regulation changes and might revise it further once the details of the single-payer Pharmacareprogramme become clearer over the coming quarters. Despite this current lack of details, we anticipate continued steps ... Read More
-
Latin America Pharmaceuticals & Healthcare Q2 2020
... highlight that several countries in the region are ramping up policy response against thecoronavirus outbreak. Relatively increased levels of public expenditure on medical services will be maintained despite restrictions ongovernment spending due to macroeconomic dynamics. Read More
-
Chile Pharmaceuticals & Healthcare Q3 2020
... Chile over the coming quarters. Thegovernment’s stimulus package allocated USD1.4bn to the Ministry of Public Health to accelerate the Chilean emergency response.Growth in the Chilean pharmaceutical market will gradually wane in the coming years, despite ... Read More
-
Greece Pharmaceuticals & Healthcare Q3 2020
... will ensure that opportunities for innovative drugmakers remain limited on the whole, Governmenthealthcare spending relating to the Covid-19 pandemic which has hit western Europe hard due to its older, pensionable population,is likely to be high. Read More
-
Bangladesh Pharmaceuticals & Healthcare Q3 2020
... public healthcaresector capacity to respond. The private sector will fill some of the gaps and mobilise to seek solutions. Pharmaceutical andhealthcare spending will post robust growth, with Bangladesh benefiting from a well-developed local pharmaceutical sector.Economic ... Read More
-
Croatia Pharmaceuticals & Healthcare Q3 2020
... targeting age-related diseases, the government will likely maintain a long-term focus on cost containment measures.The Covid-19 pandemic poses a more immediate risk to our forecast, causing downward pressure on the economy. Withexpenditure by the Croatian ... Read More
